A Study of IMP4297 in Patients With Advanced Solid Tumors

Sponsor

Impact Therapeutics, Inc. (Industry)

Overall Status

Completed

CT.gov ID

NCT03508011

Collaborator

(none)

Enrollment

Locations

Arm

39.8

Actual Duration (Months)

28.5

Patients Per Site

0.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase I, first-in-human, open-label, dose-escalation study of IMP4297 administered orally once every day to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable. Patients with advanced breast cancer, ovarian cancer or prostate cancer are preferred. There are two stages to this study: a dose-escalation stage and a dose-expansion stage.

Condition or Disease	Intervention/Treatment	Phase
Advanced Solid Tumours Breast Cancer Ovarian Cancer Prostate Cancer	Drug: IMP4297	Phase 1

Study Design

Study Type:

Interventional

Actual Enrollment :

57 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors

Actual Study Start Date :

Aug 23, 2017

Actual Primary Completion Date :

Dec 16, 2020

Actual Study Completion Date :

Dec 16, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: IMP4297	Drug: IMP4297 The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Arm

Intervention/Treatment

Experimental: IMP4297

Drug: IMP4297

The dose levels will be escalated following a modified 3+3 dose escalation scheme.

Outcome Measures

Primary Outcome Measures

The AEs (adverse event) of single and multiple doses of IMP4297 administered to participants with advanced solid tumors. [Each visit after IMP4297 administrated (through study completion, an average of 10 months)]
Evaluate the TEAE (treatment-emergent adverse event) of IMP4297
The maximum tolerated dose (MTD) and evaluate the dose limiting toxicities (DLTs) of IMP4297 [Within 28 days after IMP4297 administrated]
Evaluate DLT and determine the MTD

Secondary Outcome Measures

Area Under Curve [AUClast, AUCINF] [Within 7 days after firstly single dose administrated]
Area Under Curve [AUClast, AUCINF] [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]
Maximum plasma concentration (Cmax) [Within 7 days after firstly single dose administrated]
Maximum plasma concentration (Cmax) [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]
Time at which Cmax occurred (Tmax) [Within 7 days after firstly single dose administrated]
Time at which Cmax occurred (Tmax) [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]
Trough Concentrations (Ctrough) [Within 7 days after firstly single dose administrated]
Trough Concentrations (Ctrough) [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]
Clearance (CL/F) [Within 7 days after firstly single dose administrated]
Clearance (CL/F) [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]
Volume of distribution (Vd/F) [Within 7 days after firstly single dose administrated]
Volume of distribution (Vd/F) [Within 16 days after first dose administrated in multiple dose cycle 1 (total 21 days in one cycle)]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Signed Informed Consent Form
18 Years to 70 Years (including 18 and 75 years)
Histologically or cytologically documented disease; incurable, advanced solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy
Eastern Cooperative Oncology Group performance status of 0 or 1
In the dose expansion stage, patients with BRCA (breast carcinoma) mutation will be enrolled. Patients with breast cancer, ovarian cancer and prostate cancer are preferred.
In the dose escalation phase, at least one assessable lesion according to the RECIST 1.1 standard; In the dose expansion phase, at least one measurable lesion according to RECIST 1.1.

Exclusion Criteria:

Inadequate hematologic and organ function, defined by the following (hematologic parameters must be assessed ≥14 days after a prior treatment, if any):
Absolute neutrophil count <1500 cells/µL
Hemoglobin < 9 g/dL
Total bilirubin > 1.5 × the upper limit of normal (ULN), with documented liver metastases total bilirubin > 3 × the ULN.
Aspartate transaminase (AST) and/or alanine transaminase (ALT) > 2.5 × the ULN, with documented liver metastases AST and/or ALT levels > 5 × the ULN.
Serum creatinine > 1.5 × the ULN, or creatinine clearance < 45 mL/min based on a documented 24-hour urine collection or Cockcroft-Gault calculation of glomerular filtration rate.
International normalized ratio (INR) > 1.5 × the ULN or activated partial thromboplastin time (aPTT) > 1.5 × the ULN.

The INR applies only to patients who do not receive therapeutic anti-coagulation.

Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy within 4 weeks prior to initiation of study treatment with the following exceptions:
Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer.
Hormone-replacement therapy or oral contraceptives.
Palliative radiation to bone metastases > 2 weeks prior to Day 1.
Adverse events from prior anti-cancer therapy that have not resolved to NCI CTCAE Grade ≤ 1, except for alopecia.
Prior therapies targeting PARP (poly-ADP ribose polymerase).
Clinical significant active infection
Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
Known human immunodeficiency virus infection
New York Heart Association Class II or greater congestive heart failure; history of myocardial infarction or unstable angina within 6 months prior to Day 1; history of stroke or transient ischemic attack within 6 months prior to Day 1
Active or untreated brain metastasis
Pregnant (positive pregnancy test) or lactating women
Male or female patients of child-producing potential unwilling to use double barrier contraception: condoms, sponge, foams, jellies, diaphragm or intrauterine device, contraceptives (oral, injectable or parenteral), implanon, or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
Inability to comply with study and follow-up procedures
Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Cancer Hospital Chinese Academy of Medical Sciences	Beijing	Beijing	China	100021
2	Fudan University Shanghai Cancer Center	Shanghai	Shanghai	China	200032

Sponsors and Collaborators

Impact Therapeutics, Inc.

Investigators

Principal Investigator: BingHe Xu, Doctor, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Principal Investigator: JunNing Cao, Doctor, Fudan University